Podcasts about therapies

Please visit answersincme.com/860/240201375-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James Michael Ramsahai, BSc, MD, PhD, FRCPC and Nan Zhao, BSc, MD, FRCPC. In this activity, experts in managing severe eosinophilic asthma discuss evidence-based strategies for personalizing biologic therapy, reducing steroid burden, and optimizing treatment in the setting of overlapping eosinophilic diseases. Upon completion of this activity, participants should be better able to: Identify strategies to individualize the selection of biologic therapies for patients with severe eosinophilic asthma based on the latest clinical and real-world evidence; Evaluate the implications of real-world data on biologic therapies for addressing airway remodeling and airway plugging; Develop steroid-sparing treatment plans and monitoring strategies for patients with severe eosinophilic asthma; and Formulate treatment plans to adjust the use of biologic therapies in patients with severe eosinophilic asthma and overlapping eosinophilic comorbidities.

In this quickie episode, we will answer a question from one of our podcast family members: “Can a virgin get BV?”. It's a complicated question, that needs explanation. PLUS, we will relate this to a former “event” from a past president- so listen until the end!1. Kim ES, Waltmann A, Duncan JA, Hood-Pishchany I.Advances in Treating Bacterial Vaginosis: Recognizing Sexual Transmission and Pipeline of Therapies. Current Opinion in Infectious Diseases. 2026. 2. Liu D, Zhang X, Zhao X, et al. Bacterial Vaginosis: Advancing Insights Into Microbial Dysbiosis. Critical Reviews in Microbiology. 2026. 3. Verstraelen H, Verhelst R, Vaneechoutte M, Temmerman M. The Epidemiology of Bacterial Vaginosis in Relation to Sexual Behaviour. BMC Infectious Diseases. 2010. 4. Verstraelen H, Verhelst R, Vaneechoutte M, Temmerman M. The Epidemiology of Bacterial Vaginosis in Relation to Sexual Behaviour. BMC Infectious Diseases. 2010.

Send a textIn this Journal Club episode, Ben and Daphna review the highly anticipated TREOCAPA trial results exploring the prophylactic use of acetaminophen for PDA closure in extremely preterm infants. They break down the study's tailored dosing regimens, safety outcomes like cholestasis, and discuss why achieving a higher rate of early ductal closure didn't necessarily translate to improved survival without severe morbidity. Plus, they share a nod to recent Neo Conference interviews and the realities of conducting clinical research in private practice. Tune in for a nuanced discussion on individualizing PDA management in the NICU!----Prophylactic Treatment of Patent Ductus Arteriosus With Acetaminophen: A Randomized Clinical Trial. Rozé JC, Cambonie G, Flamant C, Patkaï J, Mühlbacher T, Gascoin G, Rideau Batista Novais A, Tauzin M, Le Duc K, Beuchée A, Joye S, Babacheva E, Bouissou A, Ligi I, Tammela O, Plourde M, Dempsey E, Tosello B, Nguyen K, Vincent M, Andresson P, Binder C, Kruse C, Barcos Munoz F, Kuhn P, Proença E, Bartocci M, Kermorvant-Duchemin E, Nellis G, Lumia M, Giapros V, Rigo V, Sankilampi U, Mendes da Graça A, Rønnestad A, Soukka H, Mondì V, Aikio O, Torre-Monmany N, Rüegger C, Baud O, Zeitlin J, Morgan AS, Baruteau AE, Ancel PY, Carbajal R, Bouazza N, Diallo A, Levoyer L, Kemper R, Hallman M, Alberti C, Ursino M; TREOCAPA Study Group.JAMA Pediatr. 2026 Feb 16:e256150. doi: 10.1001/jamapediatrics.2025.6150. Online ahead of print.PMID: 41697673Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Not all pain comes from muscles or joints. In many cases, the real source is a trapped or irritated nerve. In this episode, Dr. Derrick Hines explains how to recognize the difference between nerve entrapment and typical musculoskeletal pain. He walks through the common symptoms of nerve irritation, why traditional pain medications often fail, and how identifying the true source of pain can completely change the treatment approach and recovery timeline.In This Episode- How nerve pain feels different from muscle or joint pain- The common symptoms of nerve entrapment (burning, tingling, radiating pain)- Why anti-inflammatories and pain medications often fail- Common nerve entrapments in the body (cluneal, ulnar, median, fibular, pudendal)- Treatments that help restore nerve mobility and blood flow- Therapies used for nerve decompression and healing- How compounds like PEA and GHK-Cu may support nerve recovery- Understanding the source of your pain is the first step toward fixing it.TikTok:https://www.tiktok.com/@drderrickInstagram:https://www.instagram.com/derrickbhines/Youtube:https://www.youtube.com/@DrDerrick

Send a textLive from the NEO Conference in Las Vegas, Ben and Daphna sit down with Dr. Tarek Nakhla to discuss his new book, Saving Babies Behind the Doors of the Neonatal Intensive Care Unit. Moving beyond standard medical textbooks, Dr. Nakhla shares how chronicling nearly 30 years of challenging patient encounters and complex family dynamics can serve as an essential guide for new trainees. The conversation highlights the therapeutic power of narrative medicine for clinicians and the profound impact of non-clinical staff on the family experience. Discover why capturing the human side of neonatology is just as critical as the clinical science.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send a textHow can a database tracking 20% of all US NICU admissions change the way we practice neonatology? Live from the NEO Conference, Ben and Daphna sit down with Dr. Veeral Tolia to discuss his groundbreaking work with the Pediatrix Clinical Data Warehouse. Dr. Tolia dives into the power of leveraging decades of observational data to supplement randomized trials—from analyzing the 50-fold increase in Precedex usage to studying natural experiments like the vitamin A shortage. The group also looks ahead to the Newborn Express dataset, exploring how socioeconomic metrics like the Child Opportunity Index might help us understand the alarming rise in neonatal vitamin K refusals.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Interview with Nidheesh Dadheech, PhD

Send a textCan groundbreaking neonatal research thrive outside of academic medicine? Live from the NEO Conference, Ben and Daphna sit down with Dr. Kaashif Ahmad, Vice President of Research at Pediatrix. Dr. Ahmad shatters the myth that community NICUs can't drive clinical science, discussing how everyday documentation in systems like Baby Steps quietly fuels hundreds of publications. He also unveils "The Parent Network," a revolutionary initiative designed to partner with family-led organizations from day one to establish comparative effectiveness trial priorities. Tune in to discover how private practice clinicians are successfully balancing bedside care with robust, meaningful research.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send a textHow will artificial intelligence fundamentally change the way we chart, teach, and monitor patients in the NICU? Live from the NEO Conference, Ben and Daphna sit down with Dr. James Barry to explore the critical need for "AI literacy" among bedside clinicians. Dr. Barry draws parallels between driver's education and safe AI use, highlighting the hidden dangers of automation complacency with AI scribes. They also discuss the exciting potential of computer vision in respiratory monitoring and how the CONCERN early warning system is quantifying nursing intuition. Join us as we navigate the guardrails of neonatology's technological future.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Melissa Urban is the co-founder and CEO of Whole30 and a renowned authority on helping people create lifelong healthy habits. She is an eight-time New York Times bestselling author whose books have sold millions of copies worldwide. Melissa has been featured by major outlets like the New York Times, The Wall Street Journal, People, Forbes, Good Morning America, and CNBC. Beyond her work in nutrition and wellness, she is a prominent keynote speaker on health, boundaries, community building, and entrepreneurship. Melissa lives in Salt Lake City, Utah, and is an active voice in the concussion community, sharing her personal experience to help others feel less alone.Episode SummaryIn this episode of the Concussion Coach Podcast, host Bethany Lewis sits down with Melissa Urban for an honest and in-depth conversation about her experience with a concussion and the years-long recovery journey that followed.Melissa shares the story of her injury in December 2018—a hit to the head during a seemingly-innocuous game of laser tag. She describes the confusing onset of symptoms, from irritability and vision problems to an unfamiliar anxiety that culminated in a terrifying panic attack. Melissa opens up about the isolating nature of her symptoms, the strain it put on her relationships, and the challenge of navigating work and motherhood while dealing with an invisible injury.With the help of a specialized physical therapy team that reached out to her, Melissa was able to get a proper diagnosis and targeted treatment. She discusses the various therapies she underwent, including work on primitive reflexes, vision training, and treatment for a POTS-like nervous system dysregulation. Melissa also shares the unexpected ways her injury affected her relationship with food and exercise, and how she navigated the emotional journey of redefining her self-worth when her identity as an "active person" was temporarily stripped away. She offers invaluable advice on self-advocacy, trusting your own experience, and finding hope during setbacks, emphasizing that while her journey was long, there is more help and hope available now than ever before.Resources and Contact Information MentionedThis list compiles all the resources, tools, and contacts Melissa Urban discussed during the interview.Melissa's Personal Links:Website: melissau.comInstagram: @melissauHer Concussion Story (Part 1): https://blog.melissau.com/p/my-concussion-story-part-1Melissa's podcast episodes she mentioned:The Work of Byron KatieCold Showers with Ed SheeranTreatments, Therapies, and Tools:Specialized Physical Therapy: Melissa stressed the importance of finding a physical or occupational therapist specializing in TBI (Traumatic Brain Injury). Her team was affiliated with Park City Hospital in Utah and had experience working with the U.S. Ski and Snowboard Team.Primitive Reflex Integration: Therapy focused on re-integrating primitive reflexes that can re-emerge after a head injury.Vision Therapy: Exercises to improve eye coordination and brain-eye connection, including the use of a Brock string.Cold Exposure (Cold Showers): Melissa found cold showers to be a "magic pill" for her symptoms. She used them as a tool to train her nervous system to remain calm under stress.Irlen Screening: A vision screening that uses colored overlays to help with visual stress and perception. Melissa mentioned a translucent lilac shade was helpful for her reading.Hyperbaric Oxygen Therapy (HBOT): Melissa tried this at a local wellness clinic and found it helpful for acute symptom relief, though she noted it was expensive and time-consuming.Loop Earplugs: She used these to dull overwhelming auditory input in places like airports and grocery stores.Environmental Modifications: Melissa emphasized using sunglasses and blue-light-blocking glasses, and avoiding fluorescent or big overhead lights whenever possible.

Dr. Steven St. Peter, Co-Founder and Managing Director of Vie Ventures, discusses his firm's unique hybrid model that combines venture capital with disease philanthropy to accelerate the development of new therapies for autoimmune diseases.  While philanthropies have excelled at funding basic research, a gap exists in translating those findings into FDA-approved drugs. Steven points out that the autoimmune field is entering a golden age, driven by insights from immuno-oncology and by AI's potential to analyze data across autoimmune diseases. Steven explains, "I've been doing venture capital for the last 30 years. I'm also a physician, but I'm very interested in how venture capital is helping bring new therapies to patients, and that's really the core of what venture capital does. So I've been doing that and am comfortable with that for a long time, as well as my co-founders. About five years ago, I joined an effort working with the disease philanthropy to help create a hybrid model. And I thought that was very interesting because these disease philanthropies are really the voice of the patient. So to the extent that you can bring disease, philanthropy, and venture capital to mix, I just think that's an incredible model, and that really is what Vie Ventures is all about." "The large disease-focused philanthropies have done a phenomenal job in funding basic science research coming out of academics and helping really define, well, what is autoimmune disease and what are the biological systems and why does that matter? And in fact, just taking the case of type 1 diabetes until the 1980s, we didn't even know that that was an autoimmune disease. And in an autoimmune disease, it's the body's immune system attacking a tissue that it shouldn't. And the consequence is that it manifests as a sort of disease. So a lot of the research foundation spent a good amount of time teasing out all that basic science, and that led to insights that then allow us to create new therapies to actually change the course of these diseases. And so as you roll the clock forward to where we are in 2026, that biology has been defined." "So what Vie Ventures does is it really allows a way for these disease foundations to reach into the translation of that fundamental discovery research to actually fund drugs that are going into patients to hopefully result in an FDA approval. And that just hasn't been done in the past because the science hadn't been defined yet, but now we're at this very exciting time, and that's the next frontier." #VieVentures #AutoimmuneDisease #VentureCapital #CARTTherapy #Immunology #PatientAdvocacy #Biotech #HealthcareInnovation #Type1Diabetes #MultipleSclerosis #Lupus #EmpoweredPatient #HealthcarePodcast #MedicalResearch #PatientCentricity #DiseasePhilanthropy #AutoimmuneDisorders #ImmuneOncology #VentureImpact vieventures.com Download the transcript here

Dr. Steven St. Peter, Co-Founder and Managing Director of Vie Ventures, discusses his firm's unique hybrid model that combines venture capital with disease philanthropy to accelerate the development of new therapies for autoimmune diseases.  While philanthropies have excelled at funding basic research, a gap exists in translating those findings into FDA-approved drugs. Steven points out that the autoimmune field is entering a golden age, driven by insights from immuno-oncology and by AI's potential to analyze data across autoimmune diseases. Steven explains, "I've been doing venture capital for the last 30 years. I'm also a physician, but I'm very interested in how venture capital is helping bring new therapies to patients, and that's really the core of what venture capital does. So I've been doing that and am comfortable with that for a long time, as well as my co-founders. About five years ago, I joined an effort working with the disease philanthropy to help create a hybrid model. And I thought that was very interesting because these disease philanthropies are really the voice of the patient. So to the extent that you can bring disease, philanthropy, and venture capital to mix, I just think that's an incredible model, and that really is what Vie Ventures is all about." "The large disease-focused philanthropies have done a phenomenal job in funding basic science research coming out of academics and helping really define, well, what is autoimmune disease and what are the biological systems and why does that matter? And in fact, just taking the case of type 1 diabetes until the 1980s, we didn't even know that that was an autoimmune disease. And in an autoimmune disease, it's the body's immune system attacking a tissue that it shouldn't. And the consequence is that it manifests as a sort of disease. So a lot of the research foundation spent a good amount of time teasing out all that basic science, and that led to insights that then allow us to create new therapies to actually change the course of these diseases. And so as you roll the clock forward to where we are in 2026, that biology has been defined." "So what Vie Ventures does is it really allows a way for these disease foundations to reach into the translation of that fundamental discovery research to actually fund drugs that are going into patients to hopefully result in an FDA approval. And that just hasn't been done in the past because the science hadn't been defined yet, but now we're at this very exciting time, and that's the next frontier." #VieVentures #AutoimmuneDisease #VentureCapital #CARTTherapy #Immunology #PatientAdvocacy #Biotech #HealthcareInnovation #Type1Diabetes #MultipleSclerosis #Lupus #EmpoweredPatient #HealthcarePodcast #MedicalResearch #PatientCentricity #DiseasePhilanthropy #AutoimmuneDisorders #ImmuneOncology #VentureImpact vieventures.com Listen to the podcast here

Send a textWhen parents fundamentally disagree on life-saving interventions in the delivery room, how do clinical teams decide the next step? Live from the NEO Conference, Ben and Daphna sit down with Dr. Mark Mercurio, Executive Director of the new Center for Pediatric Bioethics at Boston Children's Hospital. Dr. Mercurio dissects a highly complex ethical case regarding parental disagreement over resuscitation at the border of viability. Emphasizing the distinction between parental "preference" and parental "judgment," he explores the necessity of clinical humility, the hidden margins of error in gestational age dating, and how admitting our own medical uncertainty is the first step toward honest family counseling.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send a textHow does individualized medicine shape both patient trust and neonatal careers? Live from the NEO Conference, Ben and Daphna catch up with Dr. Zubin Shah, Clinical Ambassador for Pediatrix. The team explores the power of tailoring bedside conversations to individual babies—whether discussing targeted hemodynamics or framing RSV prevention with nirsevimab—rather than relying solely on generalized trial data. Dr. Shah also sheds light on the evolving landscape of neonatal recruitment, emphasizing how peer mentorship and direct networking can help new physicians find practices that balance rigorous clinical care with research and quality improvement.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send a textDoes our fear of necrotizing enterocolitis do more harm than good? In this live episode from the Neo conference, Ben and Daphna sit down with Dr. Ariel Salas to challenge the "culture of fear" surrounding neonatal nutrition. Dr. Salas argues that while we obsess over ill-defined NEC risks, we may be sacrificing the proven benefits of early feeding on sepsis reduction. From the emotional weight of "wasted" breast milk to the "illusion of control" provided by strict protocols, this conversation urges neonatologists to move toward a family-centered, evidence-based approach that prioritizes human milk over clinical hesitation.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send a textJoin Ben and Daphna live from the NEO Conference as they welcome the 2026 Legends in Neonatology Award recipient, Dr. Waldemar "Wally" Carlo. In this inspiring conversation, Dr. Carlo discusses the driving forces behind his enduring passion for clinical care and the critical need for robust bedside research. They explore how full-time clinicians can actively shape the research agenda by turning everyday diagnostic uncertainties into innovative trials. Dr. Carlo also offers a preview of his highly anticipated lecture on neonatal oxygen targets, revealing why it remains one of the most rigorously studied—yet complex—areas in modern medicine.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send a textIn this live episode from the Neo Conference in Las Vegas, we welcome back Dr. Souvik Mitra to unpack the evolving landscape of PDA management in extremely preterm infants. We dive into the recent AAP guidelines recommending against early medical treatment and explore potential unintended consequences, including rising transcatheter closure rates and delayed intervention. Dr. Mitra shares his institution's approach using the SMART-PDA criteria, highlighting the importance of treatment timing and proper patient selection. Join us for a nuanced discussion balancing large pragmatic trial data with bedside clinical judgment for our most vulnerable babies.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send a textIn this live episode from the Neo Conference in Las Vegas, we welcome back Dr. Souvik Mitra to unpack the evolving landscape of PDA management in extremely preterm infants. We dive into the recent AAP guidelines recommending against early medical treatment and explore potential unintended consequences, including rising transcatheter closure rates and delayed intervention. Dr. Mitra shares his institution's approach using the SMART-PDA criteria, highlighting the importance of treatment timing and proper patient selection. Join us for a nuanced discussion balancing large pragmatic trial data with bedside clinical judgment for our most vulnerable babies.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send a textLive from the Neo Conference in Las Vegas, Ben and Daphna sit down with Dr. Zach Anderson from Winnie Palmer Hospital to demystify the integration of Point of Care Ultrasound (POCUS) in the NICU. Moving beyond the intimidation of complex cardiac scans, Zach explains why starting with "pinch points" like vascular access or bladder volume can revolutionize bedside decision-making. From the SAFER protocol to managing the agitated infant on ECMO, this episode explores how POCUS serves as a powerful problem-solving tool that bridges the gap between clinical mystery and immediate intervention.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Please visit answersincme.com/860/240201356-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sue D. Pedersen, MD, FRCPC, DABOM; Leon Waye, MD; and Basel Bari, MD, MCFP. In this activity, experts in obesity discuss treatment management with a focus on the role of incretin-based therapies. Upon completion of this activity, participants should be better able to: Explain the rationale for managing obesity as a chronic, treatable disease; Discuss the latest evidence for incretin-based therapies in the management of obesity, including clinical outcomes and safety profiles; and Identify patients who might benefit from incretin-based therapies as part of a comprehensive treatment plan for obesity.

Send a textWhat are we actually compressing during neonatal CPR? This week on The Incubator Podcast, Ben and Daphna dive into a provocative echocardiography study out of Edmonton showing that standard chest compressions in newborns likely target the right heart and great vessels — not the left ventricle. A small sample size, but a finding that anyone who ultrasounds hearts all day will instantly recognize.Daphna presents a retrospective multicenter study from Nationwide Children's on antibiotic duration for Gram-negative bloodstream infections in the NICU. Short course (≤8 days) showed no treatment failures — while 14% of infants in the long duration group developed a multi-drug resistant organism infection. Eight days versus ten: does the difference matter? The data says yes.Ben reviews a randomized controlled trial from UAB on early vitamin D supplementation in extremely preterm infants fed human milk. Eight hundred units daily for the first two weeks appears safe and effective at achieving vitamin D sufficiency — but did it move the needle on BPD? And is that even the right question to ask?Daphna brings a QI paper from Levine Children's on universal social determinants of health screening across nine pediatric divisions, achieving 92% compliance and connecting thousands of families to resources through findhelp.org. A reminder that the tools are already there — we just have to use them.The episode wraps with Ben, Daphna, and Eli discussing Colorado's landmark paid NICU leave law — the first in the nation to require employers to provide up to 12 weeks of paid leave for parents with a baby in the NICU. What does the evidence say, and how do we advocate for this in our own states?Science, equity, and advocacy — all in one episode.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

This activity will discuss clinical and safety strategies for implementation that will translate to better care for patients and a safer handling environment for providers, patients, and caregivers. Additional details and discussion about collection, processing to final dose product, dose storage/preparation/administration, and safe handling may provide more insight and considerations applicable for pharmacy practice.  CE for this episode expires 2 years after the date it was originally published. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Sometimes autism parenting feels like you're making high-stakes decisions with incomplete information. School. Therapies. Doctors. The constant “what if.” The pressure to pick the perfect path and never regret it.In this episode, Larah sits down with her friend Nicole (mom of six boys) to talk about what it looks like to advocate for your autistic child without losing your peace or your witness.Nicole shares what led her to speak at a school board meeting, how she prepared, and what anchored her in the room: identity in Christ. They talk about decision-making through a gospel lens, why boldness doesn't have to be loud, and how to walk forward in freedom when you can only see one step at a time.Inside the episode: How to advocate without yelling, spiraling, or burning bridges Why behavior change can't come first (it has to start at the root) Making school/therapy decisions with prayer, wisdom, and margin “Lamp, not flashlight” faith for moms who want clarity now The freedom to pivot when something stops workingIf you're tired of carrying the weight of every decision like it's forever… this one will exhale for you.Find Nicole on Instagram: https://www.instagram.com/nicole_cattelona/How to Advocate & Stay Christian - https://amzn.to/40yaEme

Osteosarcoma Webinar Series: Corey Weistuch, PhD, an Assistant Attending Physicist in the Service for Predictive Informatics within the Department of Medical Physics at Memorial Sloan Kettering Cancer Center, will discuss his OutSmarting Osteosarcoma funded work on implementing personalized, adaptive therapies in osteosarcoma.Corey Weistuch, PhD, is an Assistant Attending Physicist in the Service for Predictive Informatics within the Department of Medical Physics at Memorial Sloan Kettering Cancer Center. His work is focused on developing mathematical models to understand cancer development, progression, and metastasis by integrating multimodal data. Central to this approach is the recognition that tumors occupy a finite spectrum of functional states, each characterized by distinct treatment sensitivities and metastatic tendencies that evolve over time and in response to therapy. His research centers on two primary objectives: 1) developing innovative mathematical tools to identify cancer phenotype drivers, and 2) precision modeling of cancer evolution and site-specific metastatic dissemination. By leveraging his interdisciplinary training in mathematics and biology, he collaborates closely with experimental biologists and clinicians to ensure that his computational predictions are effectively translated into tangible clinical applications and trials.The Weistuch Lab's work aims to validate targeted drug candidates for osteosarcoma (OS) using patient-derived xenograft (PDX) models, leveraging a newly developed atlas of OS transcriptional states, called archetypes, to guide personalized, adaptive treatment strategies. By testing archetype-specific therapies in different disease phases, they establish a foundation for precision-based clinical trials, ultimately with the goal of improving outcomes for patients with advanced or refractory OS.

In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including: CD19-directed CAR T-cell therapies Next-generation CD19 bispecific antibodies The evolving role of allogeneic transplant Presenters: Ibrahim Aldoss, MD Associate Professor Division of Leukemia Department of Hematology/HCT City of Hope National Medical Center Duarte, California Bijal Shah, MD, MS Senior Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, Florida Link to full program: https://bit.ly/4cRjiUi Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send a textBen and Daphna conclude Journal Club with a quality improvement study from Pediatrics titled "Improving Health-Related Social Needs Screening and Support Across a Pediatric Health Care System". The hosts discuss the successful implementation of universal social determinants of health (SDOH) screening across nine pediatric divisions at Levine Children's. They highlight the impressive results—screening compliance reaching 92%—and the practical impact of connecting families to resources like FindHelp.org, which led to a 56% resolution rate in food insecurity for positive screens. Daphna makes a personal commitment to improve resource accessibility in her own unit.----Improving Health-Related Social Needs Screening and Support Across a Pediatric Health Care System. Laroia R, Minor W, Carr A, Buitrago Mogollon T, White BB, Mabus S, Stilwell L, Ahmed A, Mehta S, Obita T, Reed S, Senturias Y, Mittal S, Horstmann S, Demmer L, Dantuluri K, Chadha A, Noonan L, Courtlandt C.Pediatrics. 2026 Feb 5:e2024070035. doi: 10.1542/peds.2024-070035. Online ahead of print.PMID: 41638605Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Drs. Cytryn, Foote, and Thummalapalli discuss recent data on HER2 testing modalities and the prevalence of HER2 positivity across hepatobiliary, upper GI, and colorectal cancers, highlighting implications for precision medicine. The conversation reviews the latest clinical trial findings and the evolving landscape of HER2-targeted therapies, with insights into optimal treatment sequencing for various GI cancer subtypes.

Send a textBen and Daphna review a randomized controlled trial published in The Journal of Pediatrics by Dr. Ariel Salas and colleagues at UAB. The study investigates whether early high-dose vitamin D supplementation (800 IU/day starting day 1) in extremely preterm infants reduces the incidence of Bronchopulmonary Dysplasia (BPD) compared to standard care (starting day 14). The hosts discuss the physiologic rationale linking vitamin D to lung development, the use of impulse oscillometry to measure lung mechanics, and the secondary findings regarding metabolic bone disease. They explore why the "physiologic rationale" doesn't always translate to clinical significance.----Early Vitamin D Supplementation in Infants Born Extremely Preterm and Fed Human Milk: A Randomized Controlled Trial. Salas AA, Argent T, Jeffcoat S, Tucker M, Ashraf AP, Travers CP.J Pediatr. 2025 Dec;287:114754. doi: 10.1016/j.jpeds.2025.114754. Epub 2025 Jul 24.PMID: 40714046 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send a textIn this episode of Journal Club, Ben and Daphna review a retrospective cohort study from Pediatrics examining antibiotic duration for uncomplicated Gram-negative bloodstream infections in the NICU. The study, a collaboration between Nationwide Children's Hospital and UT Health San Antonio, compares outcomes between short course (≤8 days) and long course (≥9 days) therapy. The hosts discuss the startling finding that while recurrence rates were similar, the long-duration group had a 14% rate of developing multi-drug resistant (MDR) infections within 90 days, compared to 0% in the short-duration group.----Duration of Antibiotic Therapy for Gram-Negative Bloodstream Infections in the Neonatal Intensive Care Unit. Djordjevich CJ, Magers J, Cantey JB, Prusakov P, Sánchez PJ.J Pediatr. 2026 Jan 17:114993. doi: 10.1016/j.jpeds.2026.114993. Online ahead of print.PMID: 41554433 Free article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/FBZ865. CME/NCPD/AAPA credit will be available until January 26, 2027.Sjögren's Disease and the B-Cell Frontier: What Clinicians Need to Know Now to Prepare for Future Therapies In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and PVI, PeerView Institute for Medical Education. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/FBZ865. CME/NCPD/AAPA credit will be available until January 26, 2027.Sjögren's Disease and the B-Cell Frontier: What Clinicians Need to Know Now to Prepare for Future Therapies In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and PVI, PeerView Institute for Medical Education. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/FBZ865. CME/NCPD/AAPA credit will be available until January 26, 2027.Sjögren's Disease and the B-Cell Frontier: What Clinicians Need to Know Now to Prepare for Future Therapies In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and PVI, PeerView Institute for Medical Education. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/FBZ865. CME/NCPD/AAPA credit will be available until January 26, 2027.Sjögren's Disease and the B-Cell Frontier: What Clinicians Need to Know Now to Prepare for Future Therapies In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and PVI, PeerView Institute for Medical Education. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/FBZ865. CME/NCPD/AAPA credit will be available until January 26, 2027.Sjögren's Disease and the B-Cell Frontier: What Clinicians Need to Know Now to Prepare for Future Therapies In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and PVI, PeerView Institute for Medical Education. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/FBZ865. CME/NCPD/AAPA credit will be available until January 26, 2027.Sjögren's Disease and the B-Cell Frontier: What Clinicians Need to Know Now to Prepare for Future Therapies In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and PVI, PeerView Institute for Medical Education. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

Dr. Tony Wyss-Coray, PhD, is a professor of neurology at Stanford School of Medicine who is discovering factors present in young blood and in exercised blood that can improve brain, heart and other organ health. We discuss how different organs age at different rates and how to accurately measure biological aging. We also discuss the specific proteins found in blood when we are young and that are increased by things such as exercise, sunlight exposure, short-term fasting, specific foods and social connection that can significantly increase vitality, restore youthful functioning of the brain and body and potentially increase lifespan. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman David: https://davidprotein.com/huberman LMNT: https://drinklmnt.com/huberman ROKA: https://roka.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00:00) Tony Wyss-Coray (00:03:00) Young vs Old Animals, Age-Related Disease (00:06:35) Blood Biomarkers, Young vs Old Humans, Alzheimer's Disease (00:12:50) Sponsors: David & LMNT (00:15:28) 'Young Blood' Factors, Rejuvenation, Stem Cells (00:20:15) Blood Banking; Dracula (00:23:10) Rates of Aging in Organs, Age Gap & Disease Risk; Risk Profiles & Therapies (00:33:02) NAD Levels & Aging, NMN Supplements (00:36:44) Vitality vs Longevity; Periods of Accelerated Aging (00:43:17) Sponsors: AG1 & Roka (00:45:22) Sunlight; Youthful Blood Factors, Exercise & Brain Function, Fasting (00:51:25) Exercise, Injury & Inflammation (00:56:18) Pro-health Factors, Klotho, GDF11, Stem Cell Injection Risk (01:02:35) Platelet-Rich Plasma (PRP); Exosomes (01:05:43) Smoking, EMFs, Plastics, Long-Term Accumulation, Fresh Foods, Organic Food (01:11:28) Sponsor: Function (01:13:16) Intermittent Fasting, Long-Term Fasting, Snacking (01:19:07) Sleep; Cerebrospinal Fluid (CSF) Factors & Cognitive Function (01:24:44) Exercise Type & Longevity; Exercise Enjoyment (01:32:02) Lifestyle Factors & Alzheimer's Risk; Cognitive Exercise; Chocolate (01:37:05) Alcohol & Social Connection; US vs European Food Culture (01:40:50) Deliberate Deep Breathing; Wearables, Sunlight & Artificial Light (01:49:13) Future Projects (01:56:40) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's episode, I welcome my friend Marcella Cox back to the podcast. Marcella is a certified IFS therapist, approved consultant, and somatic IFS assistant trainer. She's also a certified Safe and Sound Protocol (SSP) and Rest and Restore provider, and the lead author of the new guidelines for integrating IFS with these listening therapies. We talk about: The basics of polyvagal theory How our nervous system states impact our parts Why co-regulation is central to healing The difference between SSP (connection to others) and Rest and Restore (connection to Self) How listening therapies can support safety in the body and allow more Self Energy to emerge I also share my own experience trying SSP with Marcella. I experienced some surprising physical shifts and insights that came up after a few short listening sessions. If you're curious about nervous system regulation and how it can deepen your IFS work, I think you'll really appreciate this conversation. About Marcella Cox Marcella Cox, LMFT, is a therapist, author, and presenter devoted to exploring the intersection of embodiment, trauma healing, and eating disorder recovery. She is a Level 3 Certified IFS Therapist, an Approved IFS Clinical Consultant, and an Assistant Trainer for Somatic IFS, the model developed by Susan McConnell. She provides consultation and leads workshops, trainings, and retreats for professionals on IFS for disordered eating, Somatic IFS, and integrating IFS with the Safe & Sound Protocol and is the lead author of the IFS and Listening Therapies (Safe and Sound Protocol and Rest and Restore Protocol) Combined Delivery Guidelines, published through Unyte in January 2026. Marcella is the founder and executive director of Kindful Body, which provides online therapy and nutrition counseling for eating and body concerns in California. She is also the co-founder of the IFS Consultation Collective, offering weekly consultation with IFS lead trainers.  To learn more about combining IFS and Unyte's listening therapies: https://integratedlistening.com/resources/ifs-and-listening-therapies/ Marcella's SSP & IFS groups: https://www.kindfulbody.com/somatic-ifs-and-ssp-group/ Sign up for Marcella's newsletter to find out about upcoming offerings Kindful Body on Instagram - https://www.instagram.com/kindfulbody/ Episode Sponsor This episode is sponsored by Therapy Training Boston. Therapy Training Boston offers live, in-person, and online workshops, plus consultation for therapists and other helping professionals, designed to support you as a whole person while satisfying your CE requirements. All of their offerings are taught with an eye toward context, power, and relational justice, and draw on the family systems theories and best practices that shaped the IFS model. They also offer an Intensive Certificate Program in Couples and Family Therapy to help you build confidence and capacity in community.  About The One Inside I started this podcast to help spread IFS out into the world and make the model more accessible to everyone. Seven years later, that's still at the heart of all we do.  Join The One Inside Substack community for bonus conversations, extended interviews, meditations, and more. Find Self-Led merch at The One Inside store. Listen to episodes and watch clips on YouTube. Follow me on Instagram @ifstammy or on Facebook at The One Inside with Tammy Sollenberger. I co-create The One Inside with Jeff Schrum, a Level 2 IFS practitioner and coach. Resources New to IFS? My book, The One Inside: Thirty Days to Your Authentic Self, is a great place to start. Want a free meditation? Sign up for my email list and get "Get to Know a Should Part" right away. Sponsorship Want to sponsor an episode of The One Inside? Email Tammy. 

Send a textIn this episode of Journal Club, Ben and Daphna review a thought-provoking study from the Archives of Disease in Childhood titled "Chest Compression in Newborn Infants: What Anatomical Structures Are We Compressing?". The hosts explore the anatomical findings suggesting that current neonatal CPR guidelines—recommending compressions over the lower third of the sternum—may actually be targeting the right ventricle and great veins rather than the left ventricle. They discuss the implications for the "cardiac pump" vs. "thoracic pump" theories and what this means for the future of resuscitation guidelines.----Chest compression in newborn infants: what anatomical structures are we compressing? Chua CT, O'Reilly M, Surak A, Schmölzer GM.Arch Dis Child Fetal Neonatal Ed. 2026 Jan 16:fetalneonatal-2025-329582. doi: 10.1136/archdischild-2025-329582. Online ahead of print.PMID: 41545184Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Gregory Zuckerman profiles Moderna CEO Stephane Bancel and the pivotal mRNA research by Kariko and Weissman, noting the company's difficult transition from drug therapies to vaccines. 2

Send a textDr. Sheri Fink, Pulitzer Prize-winning correspondent for The New York Times and author of Five Days at Memorial, joins us for a compelling discussion on the ethics of survival. Dr. Fink, an MD-PhD, discusses her recent article "Noah is Still Here," which chronicles one family's journey with Trisomy 18—a condition once universally deemed incompatible with life. She and Eli explore the shifting paradigms of care, the tension between medical prognosis and parental hope, and the "two truths" clinicians must hold when counseling families in the grey zone. A must-listen for anyone navigating complex bioethics in the NICU. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Please visit answersincme.com/860/160204316-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tina Bhutani, MD, MAS, FAAD; and Robin K. Dore, MD. In this activity, experts in dermatology and rheumatology discuss the use of TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA. Upon completion of this activity, participants should be better able to: Discuss the rationale for using novel TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA; Review the latest evidence on the use of novel TYK2 inhibitors in patients with psoriatic disease, including PsA; and Outline multidisciplinary strategies for the optimal integration of novel TYK2 inhibitors into treatment plans for patients with psoriatic disease, including PsA.

Please visit answersincme.com/860/160204316-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tina Bhutani, MD, MAS, FAAD; and Robin K. Dore, MD. In this activity, experts in dermatology and rheumatology discuss the use of TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA. Upon completion of this activity, participants should be better able to: Discuss the rationale for using novel TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA; Review the latest evidence on the use of novel TYK2 inhibitors in patients with psoriatic disease, including PsA; and Outline multidisciplinary strategies for the optimal integration of novel TYK2 inhibitors into treatment plans for patients with psoriatic disease, including PsA.

Send a textIn this premiere episode of On with Von, The Incubator launches an exciting new collaboration with the Vermont Oxford Network (VON). Hosts Dr. Ben Courchia and Dr. Daphna Yasova Barbeau sit down with Dr. Roger Soll, President of VON, and Dr. Bob White, a pioneer in NICU design, to explore the critical "Evidence to Practice" gap in the NICU environment. Moving beyond simple neuroprotection, the conversation dives into neuropromotion, examining the impact of light, sound, and sensory inputs on the developing brain. From debunking misconceptions about retinopathy to optimizing design for family integration, this discussion offers actionable insights for every bedside clinician.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send a textHow much oxygen is enough when resuscitating extremely preterm infants? This week on The Incubator Podcast, Ben and Daphna explore the TORPIDO 30/60 trial comparing 60% versus 30% FiO2 at birth. While primary outcomes were similar, babies in the 60% group needed fewer chest compressions and less epinephrine—a signal worth discussing.They examine an Indian non-inferiority study on surfactant thresholds (40% vs 30% FiO2), where waiting until 40% meant significantly fewer intubations and shorter respiratory support for the youngest babies. Ben presents compelling Melbourne data showing growth-restricted preterm infants face six-fold higher NEC risk—even with identical feeding protocols—and discusses how critical birth history gets "lost" as babies grow.Daphna tackles therapeutic hypothermia in late preterm infants, reviewing Toronto's retrospective analysis showing 34-35 weekers experience higher mortality and more brain injury compared to 36-37 weekers. As units rewrite cooling protocols, are we moving too fast on limited evidence?The episode concludes with Ben, Daphna, and Eli discussing the repeal of "sensitive locations" protections for immigration enforcement. Through the story of a mother detained while visiting her NICU baby in Chicago, they explore how these policies impact family-centered care and highlight advocacy opportunities through the Protecting Sensitive Locations Act.Current research meets real-world NICU challenges—all in one episode.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

This episode will cover the background of cellular-based gene therapies from basic cell biology to genetic targets currently used in treatment. Experts will review the mechanisms for modifying cellular genetic material and the common viral vector platforms used in ex-vivo cellular therapy production. An overview of the steps and processes for cellular therapy preparation, manufacturing, handling and administration will be provided. Additionally, this presentation will discuss novel cellular therapy agents currently approved for use and the highly anticipated cellular therapies currently under investigation. CE for this episode expires 2 years after the date it was originally published. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Send a textIn this episode of Neo News, the team examines the intersection of immigration policy and neonatal care. We review a recent op-ed discussing the "chilling effect" of immigration enforcement on families seeking care in "sensitive locations" like hospitals. The discussion highlights a harrowing report from The 19th about a family detained by ICE while en route to the NICU, sparking a conversation on how fear impacts parental presence and follow-up adherence. The hosts explore the Protecting Sensitive Locations Act and the critical role neonatologists play in advocating for safe access to healthcare for all families.----Vernon, L., Swenson, S., & Miller, E. (2025, October). Immigration policies are creating impossible choices for NICU families. Cleveland.com.  https://www.cleveland.com/opinion/2025/10/immigration-policies-are-creating-impossible-choices-for-nicu-families-lelis-vernon-sarah-swenson-and-emily-miller.htmlBarclay, M. L. (2025, December). Postpartum immigrant detention by ICE. The 19th. https://19thnews.org/2025/12/postpartum-immigrant-detention-ice/Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send a textIn this segment, Ben and Daphna review a retrospective study from the Hospital for Sick Children comparing outcomes of therapeutic hypothermia in late preterm (34-35 weeks) versus early term (36-37 weeks) infants. They discuss the significantly higher rates of mortality, hemodynamic instability, and hypoglycemia found in the younger cohort, known as "Group 1". The hosts explore the implications of using MRI scoring systems like the Weeke score for preterm brains and debate the ethical challenges of conducting future randomized trials as clinical practice shifts away from cooling younger babies based on emerging retrospective data.----Whole-body hypothermia in late preterm and early term infants: a retrospective analysis from a neurocritical care unit. Martinez A, Cikman G, Al Kalaf H, Wilson D, Banh B, Abdelmageed W, Beamonte Arango I, Christensen R, Branson HM, Cizmeci MN.Pediatr Res. 2026 Jan 7. doi: 10.1038/s41390-025-04701-x. Online ahead of print.PMID: 41501407Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send a textIn this episode of Journal Club, Ben and Daphna review a prospective cohort study from the Journal of Perinatology that examines the care of neonates following in-utero growth restriction. The hosts unpack the critical distinction between Fetal Growth Restriction (FGR) and Small for Gestational Age (SGA), highlighting how the "decay of information" in the NICU can lead clinicians to overlook early risk factors as babies grow. They discuss the study's alarming findings regarding the six-fold increased risk of Necrotizing Enterocolitis (NEC) in SGA infants and the importance of maintaining a comprehensive medical history throughout a patient's stay.----Care of neonates following in-utero growth restriction: A prospective cohort study exploring neonatal morbidity. Alda MG, Wood AG, MacDonald T, Charlton JK.J Perinatol. 2025 Sep;45(9):1219-1225. doi: 10.1038/s41372-025-02397-9. Epub 2025 Aug 21.PMID: 40841433 Free PMC article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send a textIn this episode of Journal Club, Ben and Daphna review a non-inferiority trial from the European Journal of Pediatrics exploring surfactant administration thresholds in preterm neonates. The study, conducted in India, compares a 30% versus 40% FiO2 threshold for babies 26-32 weeks gestational age. The hosts break down the counterintuitive findings regarding respiratory support duration in younger subgroups and discuss the broader implications of using rigid FiO2 heuristics versus individualized patient assessment. They also debate how resource availability influences clinical protocols and the potential benefits of "LISA" (Less Invasive Surfactant Administration) for avoiding intubation.----Higher (40%) versus lower (30%) FiO2 threshold for surfactant administration in preterm neonates between 26 and 32 weeks of gestational age: a non-inferiority randomized controlled trial. Haq MI, Datta V, Bandyopadhyay T, Nangia S, Anand P, Murukesan VM.Eur J Pediatr. 2025 Nov 25;184(12):793. doi: 10.1007/s00431-025-06628-1.PMID: 41288797 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Lisa Mosconi is a world-renowned neuroscientist and the director of the Women's Brain Initiative at Weill Cornell Medicine, where she studies how sex differences and hormonal transitions influence brain aging and Alzheimer's disease risk. In this episode, Lisa explores why Alzheimer's disease disproportionately affects women and why longer lifespan alone does not explain their nearly twofold risk compared to men. She explains why Alzheimer's disease may be best understood as a midlife disease for women, beginning decades before symptoms appear, and how menopause represents a fundamental brain event that reshapes brain energy use, structure, and immune signaling. The conversation also examines what advanced brain imaging reveals about preclinical Alzheimer's disease, estrogen receptors in the brain, and why genetic risks such as APOE4 appear to affect women differently from men. Finally, Lisa discusses the nuanced evidence around menopause hormone therapy, the legacy of the WHI, her new CARE Initiative to cut women's Alzheimer's risk in half by 2050, and practical, evidence-based strategies to support brain health through midlife—including lifestyle, sleep, metabolism, mood, and emerging therapies such as GLP-1 agonists and SERMs (selective estrogen receptor modulators). We discuss: How Lisa's personal family history and scientific background led her to focus on the intersection of women's health, brain aging, and Alzheimer's disease (AD) [2:45]; The long preclinical phase of AD and the emotional burden carried by patients before dementia becomes severe [7:15]; How AD compares to other common forms of dementia: prevalence, pathology, symptoms, diagnostic challenges, and more [10:45]; Why AD disproportionately affects women: how AD is not simply a disease of old age or longevity but a midlife disease in which women develop pathology earlier [16:15]; Menopause as a leading explanation for women's increased Alzheimer's risk, and how advanced braining imaging can detect early changes in the brain [26:15]; How a new method for imaging estrogen receptors in the brain is changing how we think about the menopause transition [35:45]; What estrogen receptor imaging can and cannot tell us about hormone therapy's potential impact on brain health [48:45]; Lisa's studies on the relationship between levels of systemic estrogen and density of estrogen receptors in the brain [58:00]; Why blood estrogen levels poorly reflect brain estrogen signaling, and how tightly regulated brain hormone dynamics complicate our understanding of menstrual-cycle and lifestyle effects [1:02:15]; The CARE Initiative: Lisa's research program looking to slash AD rates in women [1:07:45]; The dramatic difference in AD risk between men and women associated with APOE4 [1:10:45]; What the evidence suggests about menopausal hormone therapy (MHT) and AD risk, and why timing, formulation, and uterine status appear to matter [1:12:00]; How the CARE initiative plans to study MHT and AD risk, within the practical constraints of a three-year research window [1:17:30]; How to think about starting hormone therapy during perimenopause: balancing symptom relief, hormonal variability, and individualized care [1:21:00]; Investigating selective estrogen receptor modulators (SERMs) as a targeted approach to brain health during and after menopause [1:25:00]; Why estrogen became wrongly associated with cancer risk and what the evidence actually shows [1:29:30]; Why better biomarkers are central to advancing women's Alzheimer's research [1:38:30]; Modifiable risk factors for dementia, the limitations of risk models, and questionable conclusions drawn from observational data [1:44:15]; GLP-1 agonists and brain health: exploring potential neuroprotective effects of GLP-1 agonists beyond metabolic benefits [1:49:00]; The importance of lifestyle factors in reducing risk of dementia: practical strategies for women to support brain health [1:53:45]; Why long-term, consistent lifestyle habits are essential for building cognitive resilience and protecting brain health over decades [2:01:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube